(CVD) risk factors, CV structure and function, and increases the prevalence of most CVD, including coronary heart disease (CHD) and heart failure (HF) (2,3). Nevertheless, we reported an obesity paradox in 6 studies of 22,807 patients with HF (4); a metaanalysis of 89 studies in 1.3 million patients with established CHD which confirmed a strong obesity paradox (5); and a meta-analysis by Flegal et al. (6) of 97 studies in 2.9 million people which showed that overweight subjects had a significant 6% lower mortality than subjects with normal body mass index, and that class I obesity had a strong trend of 5% lower mortality. Therefore, denying the obesity paradox in 2015 is foolish in our opinion and represents a "headin-the-sand" position, although certainly confounding factors may be involved.
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Concerning the Role of Gender Difference in Obesity Paradox in Patients With Heart Failure
Several studies demonstrate the presence of an "obesity paradox" among patients with several chronic diseases, and this obesity paradox shows that lower (rather than higher) body mass index is a risk factor for increased mortality. In particular, the presence of a significant degree of obesity (i.e., at least up to a body mass index of 30 to 35 kg/m 2 )
is associated with lower mortality (1) (2) (3) . However, when Vest and colleagues. (4) analyzed their data by gender, they surprisingly found that well-established obesity paradox is valid for women but not for men.
Most studies with a considerable amount of patients could not show such a gender-specific difference in obesity paradox (1, 2) .
Although Vest et al. (4) have adjusted their data for a variety of potential cofounders, they did not adjust for coronary artery disease (CAD). It should be considered that CAD was more frequent in men than women (4). This may have had a significant impact on the survival rate in the male study cohort. Because values gained from bicycle and treadmill are not directly comparable, how did the authors overcome these differences?
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REPLY: Concerning the Role of Gender Difference in Obesity Paradox in Patients With Heart Failure
We thank Dr. Emami and colleagues for their interest in our paper on a differential effect of excess adiposity in female and male subjects. We agree that selecting model covariates to adjust sufficiently for baseline differences between the sexes, without overfitting the model, was one of the most challenging aspects of this analysis. We opted to adjust for ischemic cardiomyopathy etiology (present for 26% of female and 54% of male subjects), which is a strong predictor of heart failure outcomes (1). We did not additionally adjust for coronary artery disease (CAD), present in 30% of female and 57% of male subjects, because ischemic etiology and CAD were highly correlated; only 3% of the cohort had a nonischemic etiology with superimposed CAD.
Both the nonischemic ( Figure 2A in the original article) and ischemic ( Figure 2B in the original article) subgroups had the same relationship between body mass index (BMI) and mortality, stratified by sex (2).
We had sparse data on brain (B-type) natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) in this 1995 to 2011 cohort. However, BNP or NT-proBNP can be problematic when risk adjusting for the impact of BMI on mortality; higher BNP is an independent predictor of mortality in heart failure (3), but higher BMI is associated with lower BNP levels (4). We agree that prognostic biomarkers that are less likely to be affected by adiposity, perhaps such as soluble Toll-like receptor-2 (ST2) (5), may add additional risk adjustment.
Very few subjects underwent a bicycle exercise stress test (n ¼ 46; 1.2%), as opposed to a treadmill exercise stress test (n ¼ 3,765; 98.8%). As expected, the median peak oxygen consumption attained by bicycletested subjects was lower than that in treadmilltested subjects (median 11.6 vs. 15.9 ml/kg/min).
However, we did not adjust for the method of stress as a model covariate because in 1.2% of the cohort, the bicycle stress method fell well below the usual frequency threshold (10%) that merits model entry.
To our knowledge, no similar analyses have used a restricted cubic spline model, which can discern nonlinear relationships between BMI and mortality that differ among subgroups. We would encourage other investigators to use this analytic technique to determine whether a sex-specific relationship between BMI and mortality exists in other large cohorts with systolic heart failure.
